Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Communication dans un congrès

Development of triamcionolone based lipid nanocapsules as platforms for ocular drug delivery

Abstract :

Triamcinolone acetonide (TAA) is considered a first-line drug by itself or as a combined treatment of several intraocular diseases such as macular edema, retinal vein thrombosis, uveitis and age-related macular degeneration. The development of TAA dosage forms is limited due to its poor solubility in water and physiologically acceptable solvents. Lipid nanocapsules (LNCs) are biocompatible systems that allow loading both hydrophobic and hydrophilic drugs. LNCs present a versatile composition and application suitable for different routes of administration. The aim of this work was to develop and characterize a novel lipid LNCs formulation containing TAA as drug delivery system.

LNCs were prepared in triplicate using an optimized phase inversion-based method described by Heurtault et al., 2002. Due to the poor solubility of TAA in the oily phase of the original formulation, two co-surfactants (captex® 500p -Glyceryl triacetate and oleic acid) in three proportions (20, 30 and 50%) were tested. The average particle size (APS), polydispersity index (PI), zeta potential (ZP) and entrapment efficacy (EE) were measured.

Acceptable results were obtained with a 20% of both co-surfactants. LNCs with captex® 500p leads to about (40±1) nm size nanoparticles with a narrow size distribution (PI less than 0.2), a negative ZP (-1.2±0.7) mV and EE (85.8±0.8) % while LNCs with oleic acid showed an APS of (35.9± 0.6) nm and a PI below 0.1 with a negative ZP (-3.6±0.6) mV and EE (87±2) %. Moreover, both systems were stable for two months.

LNCs allow encapsulation of TAA and their properties remain constant over long periods of time. Thus, LNCs are promising systems than may be a potential strategy to improve efficacy and decrease side effects of this drug so used in the treatment of intraocular diseases.

Type de document :
Communication dans un congrès
Liste complète des métadonnées
Contributeur : Okina Univ Angers Connectez-vous pour contacter le contributeur
Soumis le : dimanche 24 mai 2020 - 01:54:18
Dernière modification le : mercredi 20 octobre 2021 - 03:19:20


  • HAL Id : hal-02615976, version 1
  • OKINA : ua14396



Maria Lina Formica, Gabriela Veroniva Ullio Gamboa, Jean-Pierre Benoît, Daniel Allemandi, José Luna Pinto, et al.. Development of triamcionolone based lipid nanocapsules as platforms for ocular drug delivery. Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), 2015, Denver, United States. pp.4152. ⟨hal-02615976⟩



Consultations de la notice